Review of Therapies for Immune Thrombocytopenic Purpura

Seminars in Hematology

Volumn 43, Issue SUPPL. 5, 2006, Pages

  Bussel, James ^a   Tarantino, Michael ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; MEMBRANE COFACTOR PROTEIN; RHESUS D ANTIBODY; RITUXIMAB; STEROID; THROMBOPOIETIN; TUMOR NECROSIS FACTOR;

BLEEDING; BLOOD TOXICITY; BRAIN HEMORRHAGE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT;

EID: 33745377442     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.04.010     Document Type: Editorial

References (20)

1. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J., et al. Idiopathic thrombocytopenic purpura. a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88 (1996) 3-40
2. Cines D.B., and Bussel J.B. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 106 (2005) 2244-2251
3. Tarantino M.D., Young G., Bertolone S.J., Kalinyak K.A., Shafer F.E., Kulkarni R., et al., Acute ITP in Children Study Group. Single dose of anti-D immune globulin at 75 μg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura (ITP) in children. J Pediatr 148 (2006) 489-494
4. Bussel J.B., Graziano J.N., Kimberly R.P., Pahwa S., and Aledort L.M. Intravenous anti-D treatment of immune thrombocytopenic purpura. Analysis of efficacy, toxicity, and mechanism of effect. Blood 77 (1991) 1884-1893
5. Newman G.C., Novoa M.V., Fodero E.M., Lesser M.L., Woloski B.M.R., and Bussel J.B. A dose of 75 μg/kg/d of IV anti-D increases the platelet count more rapidly and for a longer period of time than does 50 μg/kg/d in adults with immune thrombocytopenic purpura (ITP). Br J Haematol 112 (2001) 1076-1078
6. Gaines A.R. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 95 (2000) 2523-2529
7. Gaines A.R. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 106 (2005) 1532-1537
8. Schwartz J., Eldor A., Gillis S., Guinta A., Leber M., and Bussel J.B. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 72 (2003) 94-98
9. Kojouri K., Vesely S.K., Terrell D.R., and George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura. A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104 (2004) 2623-2634
10. Fabris F., Tassan T., Ramon R., Carraro G., Randi M.L., Luzzatto G., et al. Age as the major predictor of long-term response to splenectomy in immune thrombocytopenic purpura. Br J Haematol 112 (2001) 637-640
11. Law C., Marcaccio M., Tam P., Heddle N., and Kelton J.G. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 336 (1997) 1494-1498
12. Holt D., Brown J., Terrill K., Goldsby R., Meyers R.L., Heximer J., et al. Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura. Pediatrics 111 (2003) 87-90
13. 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura. a study of 578 patients with 268 splenectomies. Br J Haematol 97 (1997) 547-550
14. Cooper N., Woloski B.M., Fodero E.M., Novoa M., Leber M., Beer J.H., and Bussel J.B. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. Blood 99 (2002) 1922-1927
15. George J.N., Raskob G.E., Vesely S.K., Moore Jr. D., Lyons R.M., Cobos E., et al. Initial management of immune thrombocytopenic purpura in adults. A randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 74 (2003) 161-169
16. Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M.A., Leonard J.P., Amadori S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125 (2004) 232-239
17. Kuter D., Bussel J.B., Aledort L.M., George J., Lyons R.M., Conklin G.T., et al. A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (pts) with immune thrombocytopenic purpura (ITP). [abstract]. Blood 104 suppl (2004) 148a
18. Newland A., Caulier M.T., Schipperus M.R., Kappers-Klunne M., Varet B.R., Watkins K., et al. An open-label, unit dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (pts) with immune thrombocytopenic purpura (ITP). [abstract]. Blood 104 suppl (2004) 567a
19. Bussel J.B., Kuter D.J., George J.N., Aledort L.M., Lichtin A.E., Lyons R.M., et al. Long-term dosing of AMG 531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura (2005) Presented at the 47th ASH Annual Meeting and Exposition, Atlanta, GA, December 10-13, (abstr 220)
20. Cooper N., Heddle N.M., Haas M., Reid M.E., Lesser M.L., Fleit H.B., et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms. Modulation of cytokine and platelet responses to IV anti-D by FcγRIIa and FcγRIIIa polymorphisms. Br J Haematol 124 (2004) 511-518